Organon & Co.
For the period ended Dec 31, 2023. Filed Feb 26, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 26, 2024
OGN$13.85-0.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Equity
Consolidated Statements of Stockholders' Equity (Deficit)
($ in millions, except shares in thousands and per share amounts)
| Common Stock · Additional Paid-In Capital · Retained Earnings and Accumulated (Deficit) · Net Investment from Merck & Co., Inc. · AccumulatedOtherComprehensiveLoss · Total | |||||||
|---|---|---|---|---|---|---|---|
| Shares · Par Value | |||||||
| Balance at December 31, 2020 | — | $— | $— | $— | $6,108 | $(622) | $5,486 |
| Net income | — | — | — | 621 | 730 | — | 1,351 |
| Other comprehensive income, net of taxes | — | — | — | — | — | 98 | 98 |
| Cash dividends declared on common stock ($0.56 per share) | — | — | — | (145) | — | — | (145) |
| Stock-based compensation plans and other | 34 | — | — | 38 | — | — | 38 |
| Net transfers from Merck & Co., Inc., including Separation Adjustments | — | — | — | 65 | 588 | 11 | 664 |
| Net consideration paid to Merck & Co., Inc. in connection with Separation | — | — | — | — | (9,000) | — | (9,000) |
| Issuance of common stock in connection with the Separation and reclassification of Net investment from Merck & Co., Inc | 253,516 | 3 | — | (1,577) | 1,574 | — | — |
| Balance at December 31, 2021 | 253,550 | $3 | $— | $(998) | $— | $(513) | $(1,508) |
| Net income | — | — | — | 917 | — | — | 917 |
| Other comprehensive loss, net of taxes | — | — | — | — | — | (51) | (51) |
| Cash dividends declared on common stock ($1.12 per share) | — | — | — | (290) | — | — | (290) |
| Stock-based compensation plans and other | 820 | — | — | 64 | — | — | 64 |
| Net transfers to Merck & Co., Inc. including Separation Adjustments | — | — | — | (24) | — | — | (24) |
| Balance at December 31, 2022 | 254,370 | $3 | $— | $(331) | $— | $(564) | $(892) |
| Net income | — | — | — | 1,023 | — | — | 1,023 |
| Other comprehensive income, net of taxes | — | — | — | — | — | 23 | 23 |
| Cash dividends declared on common stock ($1.12 per share) | — | — | — | (295) | — | — | (295) |
| Stock-based compensation plans and other | 1,256 | — | 25 | 59 | — | — | 84 |
| Net transfers to Merck & Co., Inc. including Separation Adjustments | — | — | — | (13) | — | — | (13) |
| Balance at December 31, 2023 | 255,626 | $3 | $25 | $443 | $— | $(541) | $(70) |
-57-
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.